TY - JOUR
T1 - Combination therapy of itraconazole and an acylhydrazone derivative (D13) for the treatment of sporotrichosis in cats
AU - Gremião, Isabella Dib Ferreira
AU - Pereira-Oliveira, Gabriela Reis
AU - Pereira, Sandro Antonio
AU - Corrêa, Maria Lopes
AU - Borba-Santos, Luana Pereira
AU - Viçosa, Alessandra Lifsitch
AU - Garg, Ashna
AU - Haranahalli, Krupanandan
AU - Dasilva, Deveney
AU - de Sa, Nivea Pereira
AU - Matos, Gabriel S.
AU - Silva, Vanessa
AU - Lazzarini, Cristina
AU - Fernandes, Caroline Mota
AU - Miranda, Kildare
AU - Bonilla, Jhon Jhamilton Artunduaga
AU - Nunes, Anna Letícia
AU - Nimrichter, Leonardo
AU - Ojima, Iwao
AU - Mallamo, John
AU - McCarthy, John B.
AU - Del Poeta, Maurizio
N1 - Publisher Copyright:
© 2024 Dib Ferreira Gremião et al.
PY - 2024/6
Y1 - 2024/6
N2 - Acylhydrazone (AH) derivatives represent a novel category of anti-fungal medications that exhibit potent activity against Sporothrix sp., both in vitro and in a murine model of sporotrichosis. In this study, we demonstrated the anti-fungal efficacyof the AH derivative D13 [4-bromo-N'-(3,5-dibromo-2-hydroxybenzylidene)-benzohydrazide] against both planktonic cells and biofilmsformed by Sporothrix brasiliensis. In a clinical study, the effectof D13 was then tested in combination with itraconazole (ITC), with or without potassium iodide, in 10 cats with sporotrichosis refractory to the treatment of standard of care with ITC. Improvement or total clinical cure was achieved in fivecases after 12 weeks of treatment. Minimal abnormal laboratory findings,e.g., elevation of alanine aminotransferase, were observed in four cats during the combination treatment and returned to normal level within a week after the treatment was ended. Although highly encouraging, a larger and randomized controlled study is required to evaluate the effectivenessand the safety of this new and exciting drug combination using ITC and D13 for the treatment of feline sporotrichosis.
AB - Acylhydrazone (AH) derivatives represent a novel category of anti-fungal medications that exhibit potent activity against Sporothrix sp., both in vitro and in a murine model of sporotrichosis. In this study, we demonstrated the anti-fungal efficacyof the AH derivative D13 [4-bromo-N'-(3,5-dibromo-2-hydroxybenzylidene)-benzohydrazide] against both planktonic cells and biofilmsformed by Sporothrix brasiliensis. In a clinical study, the effectof D13 was then tested in combination with itraconazole (ITC), with or without potassium iodide, in 10 cats with sporotrichosis refractory to the treatment of standard of care with ITC. Improvement or total clinical cure was achieved in fivecases after 12 weeks of treatment. Minimal abnormal laboratory findings,e.g., elevation of alanine aminotransferase, were observed in four cats during the combination treatment and returned to normal level within a week after the treatment was ended. Although highly encouraging, a larger and randomized controlled study is required to evaluate the effectivenessand the safety of this new and exciting drug combination using ITC and D13 for the treatment of feline sporotrichosis.
KW - Sporothrix
KW - anti-fungal therapy
KW - cats
KW - fungal infection
KW - itraconazole
KW - sporotrichosis
KW - terbinafine,acylhydrazone
UR - https://www.scopus.com/pages/publications/85195279203
U2 - 10.1128/spectrum.03967-23
DO - 10.1128/spectrum.03967-23
M3 - Article
C2 - 38647345
AN - SCOPUS:85195279203
SN - 2165-0497
VL - 12
JO - Microbiology Spectrum
JF - Microbiology Spectrum
IS - 6
ER -